> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-238/
- Published: 2019-09-15T12:00:00.000Z
- Updated: 2026-09-15T01:49:56.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145014

[**Guide on Special 510(k) Program**](https://www.fdaweb.com/guide-on-special-510-k-program/)  
*Federal Register* notice: FDA makes available a final guidance entitled “The Special 510(k) Program.” 09/13/2019  

[**FDA Posts 9 OMB-approved Info Collections** ](https://www.fdaweb.com/fda-posts-9-omb-approved-info-collections/)*Federal Register* notice: FDA posts a list of ninee information collections that have been approved by OMB. 09/13/2019  

[**Science Board to Discuss CBER Research**](https://www.fdaweb.com/science-board-to-discuss-cber-research/)  
*Federal Register* notice: FDA announces a 10/7 Science Board meeting to hear CBER’s response on its research program. 09/12/2019  

[**Hearing on Fecal Microbiota for Transplantation**](https://www.fdaweb.com/hearing-on-fecal-microbiota-for-transplantation/)  
*Federal Register* notice: FDA announces an 11/4 public hearing to obtain input on the use of fecal microbiota for transplantation to treat Clostridium difficile infection. 09/12/2019  

[**Regulatory Review Period for Edwards Aortic Bioprosthesis**](https://www.fdaweb.com/regulatory-review-period-for-edwards-aortic-bioprosthesis/)  
*Federal Register* notice: FDA determines the regulatory review period for patent extension purposes for Edwards Lifesciences’ Pericardial Aortic Bioprosthesis. 09/12/2019  

[**Calcimar Not Withdraw Due to Safety/Efficacy**](https://www.fdaweb.com/calcimar-not-withdraw-due-to-safety-efficacy/)  
*Federal Register* notice: FDA determines that Sanofi Aventis’ Calcimar (calcitonin salmon) injection, 200 IU/mL was not withdrawn from sale due to safety or effectiveness reasons. 09/11/2019  

[**Aegea Vapor System Regulatory Review Period** ](https://www.fdaweb.com/aegea-vapor-system-regulatory-review-period/)*Federal Register* notice: FDA determines for patent extension purposes the regulatory review period for Tsunami MedTech’s Aegea Vapor System, indicated for ablation of the endometrial lining of the uterus. 09/11/2019